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The therapeutic effects of vitamin C and β-carotene on chronic liver diseases have not yet ben fully 
demonstrated and their application as dietary intakes or supplements lacks strong experimental backing. We 
aimed at investigating the therapeutic efficacy of these vitamins on hepatic fibrogenesis caused by carbon 
tetrachloride (CCl4)-intoxication in rats. Four groups of albino rats were used: group 1 (control) received only 
saline, whereas groups 2-4 were injected intraperitoneally with 0.5 mL/kg body weight CCl4 every 3 days plus 
pentobarbital (0.3 mg/L) in drinking water for 10 weeks; after which CCl4 and pentobarbital were stopped and 
the animals in group 2 were allowed to rest, while those in groups 3 and 4 were treated with intramuscular 
injections (100 mg/kg/day) of vitamins C and β-carotene, respectively, for further 2 weeks. CCl4 plus 
pentobarbital resulted in well established fibrosis as ociated with notable steatosis and ballooning. Treatment 
with vitamin C or β-carotene modulated CCl4-induced liver pathology, as reflected by significantly lower 
histological scores (p<0.05). Vitamin C intervention was also associated with significantly lower levels of liver 
enzymes, unlike β-carotene. We conclude that compared to β-carotene, vitamin C significantly ameliorated 
both biochemical and histological changes in CCl4-induced liver disease and that both vitamins separately 
attenuated liver fibrosis.  
© 2012 International Formulae Group. All rights reserved. 
 




Liver fibrosis is a common sequel of 
chronic liver diseases of whatever aetiology 
and is associated with high morbidity and 
mortality in affected patients (Wasmuth and 
Weiskirchen, 2010). Perceived as a wound-
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healing response to a sustained liver injury (Li 
and Friedman, 1999), it may progress to 
cirrhosis and eventual liver failure (Wallace et 
al., 2008). The mechanisms underlying 
hepatic fibrosis are not entirely understood, 
but an increasing body of experimental and 
clinical data suggests a concurrent 
involvement of several key factors, including 
oxidative stress (Brenner, 2009) as a result of 
increased production of reactive oxygen 
species (ROS), thus overwhelming the cellular 
antioxidant defense mechanisms (Ha et al., 
2010). Oxidative stress may prompt the 
quiescent hepatic stellate cells (also known as 
fat-storing or Ito cells) into proliferative, 
contractile myofibroblasts (Li and Friedman, 
1999; Friedman, 2008), which might also be 
sensitive to cytokines and chemokines 
secreted by liver-resident immuno-competent 
cells such as macrophages (Wallace et al. 
2008; Wasmuth and Weiskirchen, 2010). 
Besides, continuous chemical or viral insults 
to the liver may also trigger several cascades 
of both cellular and extra-cellular reactions 
leading to increased production of collagen by 
the proliferating myofibroblasts (Li and 
Friedman, 1999; Friedman, 2008).  
To-date, there seems to be no effective 
and well-tolerated anti-fibrotic therapy, and 
the current treatment of hepatic fibrosis is 
only limited to either withdrawal or 
eradication of the injurious agent (Henderson 
and Forbes, 2008). A number of anti-fibrotic 
therapies such as colchicine for alcoholic 
cirrhosis (Cortez-Pinto et al., 2002), and 
interferon-gamma-1B for chronic hepatitic C 
(Pockros et al., 2007) have been tested in 
clinical trials but these have been met with 
poor success, as indeed, even the most recent 
efforts are just only promising (Ghiassi-Nejad 
and Friedman, 2008; Cohen-Naftaly and 
Friedman, 2011). However, several 
epidemiological studies have quite strongly 
associated high intake of fruits and vegetables 
with low incidences of chronic and/or 
degenerative diseases (Corrao et al., 2004; 
Martinez-Gonzalez et al., 2011).  
Dietary components such as 
carotenoids (Krinsky, 1998; Paiva and 
Russell, 1999) and vitamin C (Padayatty et al 
2003) have been pursued for their therapeutic 
potential in chronic diseases. Owing to their 
antioxidant properties (Ha et al., 2010) they 
are cautiously considered to protect tissues 
against ROS-mediated injury (Seifert et al., 
1995; Oyimbo et al., 2006). Nevertheless, 
both experimental and clinical studies on the 
role of dietary antioxidants in liver diseases 
have so far led to mixed findings (Bjelakovic 
et al., 2011). The aim of the present study was 
to evaluate the therapeutic effects of vitamin 
C and β-carotene, respectively, against carbon 
tetrachloride (CCl4) induced liver fibrosis in 
rats.     
 
MATERIALS AND METHODS 
For this study, male Wistar albino rats 
(total number = 38), weighing between 190-
210 g each were purchased from the Small 
Animal Breeding House (Makerere University 
College of Veterinary Medicine and Animal 
resources, Kampala). The methods involving 
the use of animals were approved by the 
National Council of Science and Technology 
in Uganda (UNCST), through Makerere 
University Research & Publication Ethical 
Committee on the Care and Use of Laboratory 
Animals. The animals were handled humanely 
and allowed free access to food and drinking 
water throughout the study period, and the 
investigators fully complied with the statutory 
and institutional regulations.   
  
Chemicals and reagents 
The chemicals and reagents were of 
analytical grade (AnalaR) and they included 
vitamin C (ascorbic acid), solvents toluol and 
isopropanol which were obtained from BDH 
Laboratory Supplies, Poole, England. Beta 
carotene (a water-soluble derivative) was 
purchased from Pharminnova N.V., Waregem 
(Belgium), and sodium pentobarbital from 
Certa N.V., Braine-l’Alleud (Belgium). Olive 
oil was a product of Loreto Speciality Foods, 
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Espartinas (Spain). Paraffin wax (paraplast 
plus) came from McCormick Scientific, St. 
Louis (USA), and stains haematoxylin, eosin 
and Masson’s trichrome were from Merck 
Chemicals Co. (USA). 
 
Experimental design  
The rats were randomly divided into 
four groups of 8 or 10 animals each and 
allowed one (1) week of acclimatisation to the 
laboratory environment. The 4 groups were 
treated as follows: Group 1 (the controls) 
received intraperitoneal (IP) injections of 
0.9% saline every 3 days for 10 weeks. 
Groups 2, 3 and 4 were injected 
intraperitoneally (IP) with 0.5 mL/kg body 
weight CCl4 (diluted 1:1 with olive oil) every 
3 days plus pentobarbital (0.3 mg/L) in 
drinking water for 10 weeks. At the end of 
this period, CCl4 and pentobarbital treatments 
were stopped. The animals in group 2 
received neither of the vitamin treatments 
while those in groups 3 and 4 were treated 
with intramuscular (IM) injections (100 
mg/kg/day) of vitamins C and β-carotene, 
respectively, for further 2 weeks. In this 
protocol, the minute amounts of pentobarbital 
in drinking water were to boost CCl4 toxicity 
in rats as previously reported (McLean et al., 
1969; Wamutu, et al., 2011). The CCl4 and 
vitamin dosages used were adapted from the 
existing literature (Canturk et al., 1999; Abe et 
al., 2007). At week 12, the rats in all groups 
were deeply anaesthetised and bled by cardiac 
puncture. The blood was collected for 
biochemical analyses and the livers were 
removed for histological examination. 
 
Biochemical measurements 
The serum enzyme activities of alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase 
(ALP) and gamma glutamyltranspeptidase 
(GGT) as well as the total bilirubin (Tbil) 
serum levels were measured using a Clinical 
Chemistry automated analyser, Cobas Integra 
400 Plus (Roche Diagnostics, GMBH, 
Germany), a facility located at Clinical 
Chemistry Laboratory of Mulago Hospital 
Complex, the National Referral Hospital in 
Kampala, Uganda.  
 
Histological examination 
For histological examinations, whole 
livers were quickly removed, rinsed in cold 
phosphate buffered saline (PBS), mopped dry 
and weighed. Small portions of the liver 
tissues were randomly cut from at least 2 
different lobes and fixed in 10% buffered 
formalin. The tissues were processed 
according to Bancroft and Gamble (2002) and 
paraffin-embedded tissue blocks were 
sectioned (5 µM thickness) using a bench 
microtome (MICROM International, GmbH, 
model STP120, Germany). The sections were 
subsequently deparaffinised and stained with 
haematoxylin and eosin (H&E). To evaluate 
the degree of hepatic fibrosis, Masson’s 
trichrome stain was used as delicate septa 
characteristic of early bridging fibrosis may 
not be easily observable on H&E (Harris EI et 
al., 2009). The slides were viewed under light 
microscopy to compare the experimental and 
control liver morphology. The 
histopathological changes were scored by a 
qualified pathologist blinded of the study 
groups using a modification from Bedossa and 
Poynard (1996) and Brunt et al. (1999) 
systems of grading and staging.  The major 
histological changes observed were subjected 
to a scoring system described in Table 1.  
 
Statistical Analysis 
The data were analysed using SPSS 
version 15 software for Windows (SPSS Inc., 
Chicago IL, USA). Biochemical data were 
expressed as mean ± SEM. The differences 
among different groups were determined 
using unpaired Student’s t-test followed by a 
post-hoc test. Histology scores were analysed 
using Kruskal-Wallis non-parametric test.  P-
values of less than 0.05 were considered to be 
significant. 
 




Carbon tetrachloride (CCl4) IP 
injections in albino rats plus small amounts of 
pentobarbital in drinking water for 10 weeks 
led to substantial non-uniform nodularity on 
the liver surfaces. The livers in group 2 (CCl4 
alone) exhibited a strong yellow tint, 
apparently manifesting severe anomaly. 
Examination under light microscopy of the 
sections from group 2 revealed thick fibrotic 
septa associated with some degree of 
hepatocytic ballooning and steatosis (Figure 
1). On intervention, IM treatment with either 
vitamin C or β-carotene for 2 weeks after 
CCl4 resulted in significantly less severe liver 
histology in groups 3 (Figure 2) and 4 (Figure 
3), respectively, as expressed by significantly 
lower scores for ballooning (Figure 4), 
steatosis (Figure 5) and fibrosis (Figure 6) in 
the vitamin-treated groups. The changes in all 
experimental groups (whether treated with 
vitamin or not) were strongly associated with 
severe portal, periportal mixed lymphocytic 
infiltrates and neutrophilic granulocytes. This 
inflammation, however, was not significantly 
(p>0.05) different between the vitamin-treated 
groups and CCl4 untreated group (Table 2). 
The damage of the liver was further 
investigated by assaying for indicator 
enzymes in the serum. Typically, serum ALT, 
AST, ALP, and GGT were measured in both 
the control and the test groups. Biochemical 
results indicated significantly higher (p<0.05) 
levels of serum ALT and AST in CCl4 group 2 
compared to the control (Figure 7). Vitamin C 
and  β-carotene intervention in groups 3 and 4, 
respectively, led to significantly lower levels 
of these serum transaminases as compared to 
CCl4 group 2 which remained untreated (all 
p<0.05). GGT and ALP seemed to follow the 
same pattern (Figure 7), with their respective 
levels highly raised in CCl4 group 2 (p<0.05). 
Moreover, vitamin treatment in groups 3 and 
4 was associated with significantly low 
activity levels of these enzymes when 







Figure 1: Liver section from group 2 given CCl4 for 10 weeks; No intervention. Note 
the significant fibrosis and moderate steatosis (Masson’s trichrome, x20). 
 
 







Figure 2: Liver histology section from group 3 given CCl4 for 10 weeks, then treated 
with vitamin C for 2 weeks. Less fibrosis and almost no steatosis are observed 






Figure 3: Liver histology section from group 4 given CCl4 for 10 weeks, then treated 








Compared to CCl4 group,*p<0.05 (+VitC and +BetaC groups). Abbreviations: CCl4,  
carbon tetrachloride; VitC, vitamin C; BetaC, β-carotene. 
 
Figure 4: Histogram showing the number of animals for each grade of ballooning in the control and 




Dietary vitamins have been suggested 
to be modulators of liver disease but the 
information available to date shows mixed 
results. We examined the possible effects of 
vitamin C and β-carotene on liver injury 
caused by chronic CCl4 intoxication in rats. 
CCl4 administration IP plus minute amounts 
of pentobarbital in drinking water for 10 
weeks resulted in well established fibrosis 
associated with notable steatosis and 
ballooning of the hepatocytes. CCl4 also 
significantly increased activity levels of serum 
ALT, AST, GGT and ALP. These changes are 
consistent with several previous studies that 
used CCl4-animal model for induction of 
experimental liver disease (Seifert et al., 1995; 
Canturk et al., 1999; Abe et al., 2007). 
Vitamin C intervention significantly 
attenuated most of the histological and 
biochemical changes when compared to the 
CCl4 group which was not treated with the 
vitamin. This water-soluble vitamin is 
considered to be a powerful quencher of free 
radicals/reactive species, in part, because of 
its ease to oxidation and the resulting 
semidehydroascorbic acid radical assumes 
relative stability (Halliwell, 2001; Griffiths & 
Lunec, 2001). ROS (oxygen derived free 
radicals) are increasingly being incriminated 
as playing pivotal role in many chronic 
diseases such as hepatic fibrogenesis 
(Brenner, 2009). More recently vitamin C has 
been reported to be effective in modulating 
different kinds of liver damage as 
demonstrated by various animal models 
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most probably through its ability to neutralise 
ROS, although such benefit would perhaps be 
less than anticipated or even elusive in human 
studies (Padayatty et al., 2003). Nonetheless, 
vitamin C, in combination with other vitamins 
such as vitamin E, has shown favourable anti-
fibrotic effects in patients with non-alcoholic 
steatohepatitis (Harrison et al., 2003) and fatty 
liver disease (Ersoz et al., 2005). Moreover, 
several disease conditions that are perceived 
to be caused or exacerbated by free radicals 
are also associated with low plasma and tissue 
vitamin C levels. Furthermore, vitamin C 
concentration could diminish in patients with 
liver diseases and possibly other chronic 
disorders (Padayatty et al. 2003). It may not 
be clear, though, whether sub-optimal vitamin 
C in such patients contributes to liver 
diseases, is a consequence of the 
pathophysilogical process or just a coincident 
entity. Nevertheless, vitamin C may still be a 






Compared to CCl4 group, *p<0.05 (+VitC group); n.s.Not significant (+BetaC group).  
Abbreviations: CCl4, carbon tetrachloride; VitC, vitamin C; BetaC, β-carotene. 
 



































Compared to CCl4 group,*p<0.01 (+VitC & +BetaC groups).  
Abbreviations: CCl4, carbon tetrachloride; VitC, vitamin C; BetaC, β-carotene. 
 
Figure 6: Histogram showing the number of animals for each grade of fibrosis in the control and 
experimental groups.  
 
 
Similarly, β-carotene, applied in 
moderate doses led to lower scores for most of 
the histopathologic alterations, except for 
hepatic inflammation (p>0.05) as  compared 
to the CCl4 group 2. This was surprising 
because in previous studies, β-carotene had 
shown limited benefit when co-administered 
with CCl4 in a prophylactic setting. It was 
shown to exacerbate steatosis and to very 
poorly influence the biochemical outcomes 
(Wamutu et al., 2011). This difference may be 
explained, perhaps partly, by the fact that in 
the former study, CCl4 was applied 
simultaneously with β-carotene, and in the 
present study, the vitamin was given after 
CCl4 and pentobarbital administration was 
stopped. Therefore, one would expect a 
conceivable self-healing of the liver rather 
than the effect of β-carotene, or the vitamin 
could have simply enhanced the reversal of 
fibrosis, without causing side effects usually 
associated with adverse interactions of this 
vitamin and other substances (Leo & Lieber, 
1999). Nonetheless, the present results 
corroborate previous findings by Seifert et al. 
(1995) and Wardi et al. (2001) in which β-
carotene was reported to have modulated the 
severity of hepatic inflammation and fibrosis. 
Nevertheless data from some clinical reports 
indicate that prolonged and continuous doses 
of vitamin A (an immediate metabolite of β-
carotene) even in would-be low “therapeutic” 
range can result in chronic liver disease 
(Geubel et al., 1991; Jorens et al., 1992) 






























 Compared to control, *p<0.05 (CCl4 group); Compared to CCl4 group 2, ** p<0.05 (+VitC group 3); §p<0.05 (+BetaC group 
4); Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamylranspeptidase; 
ALP, alkaline phosphatise. 
 
Figure 7: Serum enzyme activity levels of ALT (I ), AST (II ), GGT (III ) and ALP (IV ) in control 
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    Table 1: Numerical scores for grading and staging of major histopathhological changes in rat liver sections. 
  
Portal inflammation Lobular inflammation ♪  Ballooning† Steatosis¶  Fibrosis 
0 = none 0 = none 0 = none  0 = no steatosis  0 = no fibrosis  
1 = mild (few portal tracts) 1 = 1-2 foci 1 = few cells  1 = ≤33%  1 = mild PP  
2 = moderate (some portal tracts)  2 = 2-4 foci  2 = many  2 = 33-66%  2 = portal-PP  
3 = marked (most portal tracts) 3 = >4 foci  3 = very many   3 = >66%  3 = bridging P-P & P-C linkages  
    4 = fibrous septa, disturbed architecture, 
nodulation  
♪ Per 200 x field; † Ballooned cells; ¶ Hepatocytes involved. 
Abbreviations: P, Portal; PP, Peri-portal; P-P, Portal-portal; P-C, Portal-central.  




    Table 2: p-Values of Kruskal-Wallis non-parametric test for histology scores between CCl4 group 2 and vitamin-treated groups 3 and 4. 
 
 Inflammation  
Necrosis  Apoptosis  Ballooning  Steatosis  Fibrosis  
Portal  Lobular  
Possible scores  0-3  0-3  0-2  0-2  0-3  0-3  0-4  
VitC-treated/CCl4  0.275  0.075  0.029*  0.131  0.027*  0.043*  0.004* 
BetaC-treated/CCl4  0.316  0.165  0.049*  0.163  0.044*  0.059  0.006* 
        * p<0.05 compared to CCl4 group; CCl4, carbon tetrachloride; VitC, vitamin C; BetaC, β-carotene 
 
   
S. WAMUTU et al. / Int. J. Biol. Chem. Sci. 6(2): 559-571, 2012 
 
 569
 That β-carotene did not cause any 
complications, as reflected by our present 
results, can also be explained, at least in part, 
on the basis of its conversion to vitamin A 
(retinol) which is perceived as a potentially 
toxic, especially in the presence of other drugs 
such as alcohol. However, if the hepatic 
reserves of vitamin A are not disturbed, this 
conversion is usually well controlled and 
occurs only according to body’s needs, and 
this may have rendered the pro-vitamin A less 
toxic in our experiments. 
 
Conclusion 
Our results demonstrate that vitamin C 
significantly attenuates liver damage caused 
by CCl4 intoxication and induces reversal of 
hepatic fibrosis, including other changes in 
rats. The present results also show that β-
carotene modulates liver fibrosis without 
significantly affecting liver enzyme activities. 
Both vitamins appear promising as anti-
fibrotic agents in experimental models and 
encourage further studies. 
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